CRISPR Therapeutics AG vs Pfizer, Inc. — Stock Comparison
Q·Score Breakdown
5.2
Bearish
Overall
6.5
Neutral
Quality
Health
Growth
Valuation
Sentiment
CRSP
Clean balance sheet with low leverage (0.1× debt-to-equity).
⚠ low return on equity (-30%).
PFE
Strong profitability with 12% net profit margins.
⚠ analyst sentiment is cautious.
Analyst Consensus
BUY
Target $83.35 (+61.4%)
23 analysts
HOLD
Target $29.00 (+10.2%)
27 analysts
Fundamentals
CRSP
PFE
—
Trailing P/E
19.4×
-12.9×
Forward P/E
9.4×
0.0%
Profit Margin
12.4%
0.0%
Gross Margin
75.8%
-30.2%
ROE
8.9%
-97.6%
Revenue Growth
-1.2%
—
Earnings Growth
—
1.79
Beta
0.39
—
Price / Book
—
$5.0B
Market Cap
$149.8B
$33 – $78
52-Week Range
$22 – $29
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →